BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC has launed Lopreeza tablets (estradiol/norethindrone acetate), a menopause medication, in 0.5 mg/0.1 mg and 1 mg/0.5 mg strengths.
Amneal said Thursday that Lopreeza is the first authorized generic version of Novo Nordisk’s Activella and contains the identical formulation of estradiol/norethindrone acetate.
Both strengths of Lopreeza are now shipping, according to Amneal. The tablets are sold in 28-count dial-pack dispensers and are available through wholesalers, distributors and directly to the trade.
"With an authorized generic like Lopreeza, pharmacists are able to provide their patients with the same brand products at a lower cost," commented Chirag Patel, co-chief executive officer at Amneal. "Consistency is critical in this therapeutic category. Women currently taking Activella can now enjoy continuity of therapy by remaining on the brand product while benefiting from the generic savings."
A combination medicine, Lopreeza is indicated for the treatment of menopause symptoms such as hot flashes and vaginal changes as well as to prevent osteoporosis in menopausal women.
Annual U.S. sales of estradiol/norethindrone acetate tablets totaled $116 million as of August 2014, according to IMS Health data cited by Amneal.
